Scarica l'app Stockscreener
117.39
1.50%
1.74
Dopo l'orario di chiusura:
117.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal - Investing.com
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corp (INCY) grants RSUs and stock options to accounting chief - Stock Titan
Incyte Corp (INCY) CMO awarded RSUs, options and sells stock - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to CSO - Stock Titan
Equity grants to INCYTE CORP (INCY) R&D head and holdings - Stock Titan
Incyte (INCY) grants RSUs, options and performance shares to EVP - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to EVP - Stock Titan
Incyte (NASDAQ: INCY) awards RSUs, options and performance shares to EVP - Stock Titan
INCYTE CORP (INCY) grants CEO stock options, RSUs and performance shares - Stock Titan
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Incyte adds Halozyme’s ENHANZE tech to first-in-class myeloproliferative neoplasm therapy - AllSci
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - The AI Journal
Halozyme-Incyte Deal Aims for More Convenient INCA033989 Dosing - Stock Titan
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation - ChartMill
INCY: Incyte Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers - The AI Journal
Incyte to present Phase 1 cancer data at ESMO Congress - Investing.com
Incyte stock hits 52-week high at 118.98 USD - Investing.com
Incyte CMO Steven Stein sells $3.19m in company stock By Investing.com - Investing.com South Africa
Form 4 Incyte Corporation For: 16 July By Investing.com - Investing.com Nigeria
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte CMO Steven Stein sells $3.19m in company stock - Investing.com
Lobbying Update: $110,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Incyte (INCY) R&D chief withholds 22,919 shares to cover taxes - Stock Titan
Incyte Corp (NASDAQ: INCY) EVP reports 1,949-share RSU tax withholding - Stock Titan
Incyte Corp (NASDAQ: INCY) PAO reports 1,790 shares withheld for RSU taxes - Stock Titan
What to Expect From Incyte's Q2 2026 Earnings Report - Barchart.com
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on VWD drug data - Investing.com
H.C. Wainwright reiterates Incyte stock rating on VWD drug data By Investing.com - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (INCY) Reveals Promising Data for New Treatment in Von Wi - GuruFocus
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3 - Yahoo Finance
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types - BioBuzz
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis - Yahoo Finance
BMO raises Incyte stock price target to $112 on Opzelura strength - Investing.com Nigeria
INCY Maintained by BMO Capital -- Price Target Raised to $112 - GuruFocus
BMO raises Incyte stock price target to $112 on Opzelura strength By Investing.com - Investing.com South Africa
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disord - Benzinga
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks - Yahoo Finance
Incyte reports 81% bleeding reduction in VWD study - grafa.com
Incyte reports phase 1/2 trial results for bleeding disorder drug By Investing.com - Investing.com South Africa
Incyte reports phase 1/2 trial results for bleeding disorder drug - Investing.com
Incyte stock holds steady as pipeline progress supports long-term growth outlook - Ad-hoc-news.de
Funds slated to go to Incyte will bankroll corridor improvement program - Delaware Business Now
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Forte, First Tracks soar on CD122 success in vitiligo; celiac next - BioWorld News
Incyte stock steadies on its oncology franchise - ad-hoc-news.de
2 Fast-Growing Pharmaceutical Stocks to Buy Now - Yahoo Finance
Incyte (INCY) Set to Release Q2 2026 Earnings with Positive Mark - GuruFocus
1.50%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):